Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior.
Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior.
复制标题
Delta-9-四氢大麻酚、大麻二酚和急性拟心理状态：主要植物大麻素对人脑和行为的平衡作用。
DOI：
10.1089/can.2021.0166
复制
发表时间：
2023
影响因子：
3.8
通讯作者：
Ranganathan,Mohini
中科院分区：
文献类型：
--
作者：
Ganesh,Suhas;Cortes-Briones,Jose;SchnakenbergMartin,AshleyM;Skosnik,PatrickD;D'Souza,DeepakC;Ranganathan,Mohini
背景：THC和CBD是大麻植物中的主要植物大麻素。这些化合物对特定的大脑和行为反应的差异和可能的拮抗作用，以及其影响的机制产生了广泛的兴趣，在临床前和临床神经科学investigation.Methods：在这个双盲随机安慰剂对照平衡人体实验室研究，我们研究了三种不同剂量比的CBD：THC（1：1，2：1和3：1）对“神经噪声”，一种电生理生物标志物的精神病已知是敏感的大麻素以及主观和拟精神病的影响。结果：最低CBD（2.5 mg）：THC（0.035 mg/kg）比例（1：1）导致THC诱导的拟精神病效应（阳性和阴性综合征量表[PANSS]阳性：Anova类型统计[ATS]= 7.83，pcorrected =0.015）和神经噪声（ATS= 8.83，pcorrected =0.009）的最大衰减。进一步添加CBD并没有减少THC诱导的“高”的主观体验（对于所有CBD剂量，p>0.05）。解释：这些新的结果表明，CBD以剂量/比率依赖性方式减弱特定THC诱导的与精神病相关的主观和客观效应。鉴于大麻自由化和用于医疗适应症的全球趋势日益增长，鉴于这些关键植物大麻素的潜在剂量相关相互作用，这些结果具有相当大的意义。试验注册：试验注册于clinicaltrials.gov ID：NCT 01180374。
Background:THC and CBD are the principal phyto-cannabinoids in the cannabis plant. The differential and possibly antagonistic effects of these compounds on specific brain and behavioral responses, and the mechanisms underlying their effects have generated extensive interest in pre-clinical and clinical neuroscience investigations.Methods:In this double-blind randomized placebo-controlled counterbalanced Human Laboratory Study, we examined the effects of three different dose ratios of CBD:THC (1:1, 2:1, and 3:1) on “neural noise,” an electrophysiological biomarker of psychosis known to be sensitive to cannabinoids as well as subjective and psychotomimetic effects. Healthy volunteers (n=28, 12 women) with at least one prior exposure to cannabis participated in the study.Outcomes:The lowest CBD (2.5 mg):THC (0.035 mg/kg) ratio (1:1) resulted in maximal attenuation of both THC-induced psychotomimetic effects (Positive and Negative Syndrome Scale [PANSS] positive: Anova Type Statistic [ATS]=7.83,pcorrected=0.015) and neural noise (ATS=8.83,pcorrected=0.009). Further addition of CBD did not reduce the subjective experience of THC-induced “high” (p>0.05 for all CBD doses).Interpretation:These novel results demonstrate that CBD attenuates specific THC-induced subjective and objective effects relevant to psychosis in a dose/ratio-dependent manner. Given the increasing global trend of cannabis liberalization and application for medical indications, these results assume considerable significance given the potential dose-related interactions of these key phyto-cannabinoids. Trial registration: The trial was registered in clinicaltrials.gov ID: NCT01180374.